Trial Profile
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Ezetimibe/simvastatin (Primary) ; Simvastatin (Primary)
- Indications Metabolic syndrome
- Focus Therapeutic Use
- Acronyms Merck-123
- Sponsors Merck Sharp & Dohme Corp.
- 21 Jul 2022 Status changed from not yet recruiting to completed.
- 07 Oct 2009 New trial record